Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study.

Kumarathurai P, Anholm C, Nielsen OW, Kristiansen OP, Mølvig J, Madsbad S, Haugaard SB, Sajadieh A

Cardiovascular diabetology26 Jul 2016Cited by 41 (Europe PMC)

PMID27455835PMCIDPMC4960858DOI10.1186/s12933-016-0425-2PepBankPUB-27455835

Summary

BackgroundPatients with type 2 diabetes (T2D) and coronary artery disease (CAD) have increased risk of cardiac dysfunction. The diabetic heart is characterized by increased fatty acid oxidation and reduced glucose uptake resulting in reduced cardiac efficiency. Glucagon-like peptide-1 (GLP-1) has shown to increase myocardial glucose uptake and to improve myocardial function. We examined the effect of the GLP-1 receptor agonist, liraglutide, on the systolic function of the left ventricle (LV) in patients with T2D and stable CAD.MethodsIn this placebo-controlled crossover study, 41 subjects with T2D and stable CAD were randomized to liraglutide or placebo and underwent dobutamine stress echocardiography (DSE) and exercise tolerance test at beginning and end of each intervention. The primary endpoint was changes in LV ejection fraction. Secondary endpoints were exercise capacity and other measures of systolic function: wall motion score index (WMSI), global longitudinal strain (GLS) and strain rate (GLSR).ResultsLiraglutide, when compared to placebo, did not improve LV ejection fraction at rest (+0.54 %; 95 % CI 2.38-3.45), at low stress (+0.03 %; 95 % CI 3.25-3.32), at peak stress (+1.12 %; 95 % CI 3.45-5.69), or at recovery (+4.06 %; 95 % CI 0.81-8.93). No significant changes in WMSI were observed at any stress levels. GLS and GLSR at rest did not improve. The maximal exercise capacity estimated by metabolic equivalents was not affected by liraglutide.ConclusionIn conclusion, liraglutide did not improve the systolic function of the left ventricle during DSE or the exercise capacity in patients with T2D and stable CAD. Clinical Trial Registration http://www.clinicaltrials.gov (unique identifier: NCT01595789).

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and stable coronary artery disease, liraglutide did not improve left ventricular ejection fraction versus placebo at rest, low stress, peak stress or recovery.
In plain wordsIn people with type 2 diabetes and coronary artery disease, liraglutide did not improve the heart's pumping fraction compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeLeft ventricular ejection fraction change (rest, low stress, peak stress, recovery)
Study
n = 41
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
LVEF change
0.54%
rest
LVEF change
0.03%
low stress
LVEF change
1.12%
peak stress
LVEF change
4.06%
recovery
Source sentences
Summary
Liraglutide, when compared to placebo, did not improve LV ejection fraction at rest (+0.54 %; 95 % CI 2.38-3.45), at low stress (+0.03 %; 95 % CI 3.25-3.32), at peak stress (+1.12 %; 95 % CI 3.45-5.69), or at recovery (+4.06 %; 95 % CI 0.81-8.93).
1 context sentence(design, population, supporting numbers)
Summary · context
In this placebo-controlled crossover study, 41 subjects with T2D and stable CAD were randomized to liraglutide or placebo and underwent dobutamine stress echocardiography (DSE) and exercise tolerance test at beginning and end of each intervention.
Show in the study text Report a problemFND-2745583501
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and stable coronary artery disease, liraglutide caused no significant change in wall motion score index at any stress level versus placebo.
In plain wordsIn people with type 2 diabetes and coronary artery disease, liraglutide did not change heart wall motion compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeWall motion score index
Study
n = 41
Comparator
Placebo
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
No significant changes in WMSI were observed at any stress levels.
1 context sentence(design, population, supporting numbers)
Summary · context
In this placebo-controlled crossover study, 41 subjects with T2D and stable CAD were randomized to liraglutide or placebo and underwent dobutamine stress echocardiography (DSE) and exercise tolerance test at beginning and end of each intervention.
Show in the study text Report a problemFND-2745583502
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and stable coronary artery disease, liraglutide did not improve global longitudinal strain at rest versus placebo.
In plain wordsIn people with type 2 diabetes and coronary artery disease, liraglutide did not improve a measure of heart muscle strain at rest compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeGlobal longitudinal strain at rest
Study
n = 41
Comparator
Placebo
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
GLS and GLSR at rest did not improve.
1 context sentence(design, population, supporting numbers)
Summary · context
In this placebo-controlled crossover study, 41 subjects with T2D and stable CAD were randomized to liraglutide or placebo and underwent dobutamine stress echocardiography (DSE) and exercise tolerance test at beginning and end of each intervention.
Show in the study text Report a problemFND-2745583503
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and stable coronary artery disease, liraglutide did not improve global longitudinal strain rate at rest versus placebo.
In plain wordsIn people with type 2 diabetes and coronary artery disease, liraglutide did not improve heart muscle strain rate at rest versus placebo.
Peptide
Liraglutide
Outcome
No significant changeGlobal longitudinal strain rate at rest
Study
n = 41
Comparator
Placebo
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
GLS and GLSR at rest did not improve.
1 context sentence(design, population, supporting numbers)
Summary · context
In this placebo-controlled crossover study, 41 subjects with T2D and stable CAD were randomized to liraglutide or placebo and underwent dobutamine stress echocardiography (DSE) and exercise tolerance test at beginning and end of each intervention.
Show in the study text Report a problemFND-2745583504
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and stable coronary artery disease, maximal exercise capacity was not affected by liraglutide versus placebo.
In plain wordsIn people with type 2 diabetes and coronary artery disease, liraglutide did not change exercise capacity compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeMaximal exercise capacity (metabolic equivalents)
Study
n = 41
Comparator
Placebo
Analysis
Secondary
Outcome group
Exercise and physical function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
The maximal exercise capacity estimated by metabolic equivalents was not affected by liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this placebo-controlled crossover study, 41 subjects with T2D and stable CAD were randomized to liraglutide or placebo and underwent dobutamine stress echocardiography (DSE) and exercise tolerance test at beginning and end of each intervention.
Show in the study text Report a problemFND-2745583505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01595789

The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes

Haugaard, Steen Bendix, M.D., DMScn = 41May 2012 to Jul 2015

Coronary Artery Disease · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 7 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.